NEWSMAX @NEWSMAX
Vaccine maker Novavax Inc said on Tuesday its COVID-19 shot retooled against the omicron BA.1 variant showed a strong immune response as the fourth dose and met the main goal of strain change in a late-stage study.https://t.co/brBvJwCZgO — PolitiTweet.org